Editas Medicine, Inc. and Azzur Cleanrooms on Demand (COD), Azzur Group company, announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine's experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization. The expanded agreement includes compliant cleanroom space and labs services at Azzur's COD site in Devens, Massachusetts. Editas Medicine has utilized Azzur's services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 for the treatment of sickle cell disease and beta thalassemia, since 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -4.32% | -6.17% | -47.48% |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
05-09 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.48% | 438M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. and Azzur Cleanrooms on Demand, Azzur Group Company, Expand their Multi-Year Contract to Support Scaling of EDIT-301